Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]
, 2019 ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K +9 more
core +2 more sources
Current indications for denosumab in benign bone tumours
EFORT Open Reviews, 2023 Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK–RANKL pathway. It promotes the apoptosis of osteoclast-like giant cells, a secondary ossification and connective tissue formation. Given its high efficacy, denosumab
Antal Imre +2 more
doaj +1 more source
Journal of Clinical Endocrinology and Metabolism, 2023 Context Denosumab is an effective treatment for many receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated disorders but there are potential safety considerations and limited data to guide its use in children and adolescents.
Joel A. Vanderniet +9 more
semanticscholar +1 more source
SAT-512 Severe Hypocalcemia Presenting as Status Epilepticus after Denosumab Use in Metastatic Prostate Cancer [PDF]
, 2019 Introduction: Denosumab decreases the incidence of skeletal-related events in patients with metastatic bone disease and is used routinely as part of the therapeutic strategy for various cancers.
Aziz, Ammara, Saeed, Zeb
core +1 more source
Journal of Bone and Mineral Research, 2022 It is uncertain whether the risk of vertebral fracture (VF) and multiple vertebral fractures (MVFs; ≥2 VFs) after denosumab (DMAb) discontinuation is related to treatment duration.
F. Cosman +3 more
semanticscholar +1 more source
Medication-related osteonecrosis of the jaw: clinical and practical guidelines [PDF]
, 2016 Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of progressive bone destruction in the maxillofacial region of patients.
Allen +42 more
core +2 more sources
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review
Advances in Therapy, 2021 The fully human monoclonal antibody denosumab was approved for treatment of osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces clinically meaningful increases in bone mineral density (BMD) and reduces fracture risk at
D. Kendler +3 more
semanticscholar +1 more source
Effect of risedronate on bone loss at discontinuation of denosumab
Bone Reports, 2020 Purpose: The occurrence of multiple vertebral fractures was reported after denosumab discontinuation. The use of bisphosphonates following denosumab has been suggested to prevent this bone loss.
Michel Laroche +4 more
doaj +1 more source
The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention [PDF]
, 2018 Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition that can considerably affect the quality of life of patients ...
Bedogni, Alberto +7 more
core +2 more sources
Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
JCEM Case Reports, 2023 Denosumab is a RANK-L inhibitor used off-label as a treatment for a variety of pediatric bone disorders, including aneurysmal bone cysts (ABC). Rebound hypercalcemia is a known side effect after denosumab therapy and is more commonly reported in ...
Anne Gandolfi, Sarah Shaaban
semanticscholar +1 more source